Merck Gains Early-Stage Protease Inhibitor For HIV/AIDS Through Ambrilia Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing agreement includes rights to Ambrilia's lead compound PPL-100 in Phase I development as a once-daily, first-line oral therapy for HIV.
You may also be interested in...
Ambrilia To Announce U.S. Octreotide Partner By Year-End
The Canadian company will pair with Teva in Europe on its formulation of Novartis’ acromegaly therapy Sandostatin LAR.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.